Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, USA; Department of Neurosurgery, University of Tokyo Hospital, Tokyo, Japan.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
World Neurosurg. 2021 May;149:e51-e62. doi: 10.1016/j.wneu.2021.02.091. Epub 2021 Feb 26.
The collision of pituitary adenoma and craniopharyngioma is extremely rare and thus there remains a paucity of data.
We described a patient from our institution. We also performed a systematic review and subsequent quantitative synthesis of the literature (n = 21) and our institutional case to yield an integrated cohort, and a descriptive analysis was carried out.
Twenty-two patients (15 males and 7 females) were included in the integrated cohort. The median age was 47.0 years (range, 8-75 years). The tumor subtypes were 5 somatotropic, 5 lactotropic, 4 nonfunctioning, 3 gonadotropic, 2 corticotropic, 1 plurihormonal, and 1 silent subtype 3 for pituitary adenomas, and 19 adamantinomatous, 2 papillary, and 1 unknown subtype for craniopharyngiomas. Three different radiographic patterns were observed: solid mass with cystic component (n = 5), coexistence of two distinct solid components (n = 3), and a mixed-intensity solid mass (n = 5). The first 2 were consistent with histologically separate collision, whereas the third was consistent with histologically admixed collision. Among 19 patients in whom the postoperative course was recorded, a secondary intervention was required in 14 (73.7%) because of tumor progression or residual. The recurrence rate after gross total resection was 33.3%. Postoperative hormone replacement was required in 33.3%. The 10-year cumulative overall survival was 73.1%.
Most craniopharyngiomas were adamantinomatous. There are 2 types of collisions: separated and admixed. Tumor control, overall survival, and endocrinologic remission are more challenging to achieve than for solitary tumors, but gross total resection of both tumors is important for satisfactory tumor control.
垂体腺瘤和颅咽管瘤的碰撞极为罕见,因此数据匮乏。
我们描述了一位来自我们机构的患者。我们还对文献(n=21)和我们机构的病例进行了系统回顾和随后的定量综合,得出了一个综合队列,并进行了描述性分析。
综合队列中包括 22 名患者(15 名男性和 7 名女性)。中位年龄为 47.0 岁(范围,8-75 岁)。肿瘤亚型为 5 种生长激素型、5 种催乳素型、4 种无功能型、3 种促性腺激素型、2 种促肾上腺皮质激素型、1 种多激素型和 1 种静默型 3 型垂体腺瘤,以及 19 种造釉细胞瘤型、2 种乳头瘤型和 1 种未知型颅咽管瘤。观察到三种不同的影像学模式:囊性成分的实性肿块(n=5)、两个不同的实性成分共存(n=3)和混合强度的实性肿块(n=5)。前两种与组织学上的分离碰撞一致,而第三种与组织学上的混合碰撞一致。在记录了术后过程的 19 名患者中,有 14 名(73.7%)因肿瘤进展或残留需要二次干预。大体全切除后的复发率为 33.3%。术后需要激素替代治疗的有 33.3%。10 年总生存率为 73.1%。
大多数颅咽管瘤为造釉细胞瘤型。有两种碰撞类型:分离和混合。与单一肿瘤相比,肿瘤控制、总体生存和内分泌缓解更具挑战性,但同时切除两种肿瘤对于满意的肿瘤控制非常重要。